NEWS: MARCH 2006

-03/10/2006-

Evotec AG and Boehringer Ingelheim reach second durg discovery milestone. To read article click here.

-03/09/2006-

FDA panel votes to return multiple sclerosis drug Tysabri to market. To read article click here.

-03/08/2006-

Neurocrine Biosciences Inc.'s Phase II clinical trials of Multiple Sclerosis drug fails. To read article click here.

Vertex Pharmaceuticals Inc.'s VX-702, a p38 MAP kinase inhibitor, meets its primary objectives in Phase II clinical trials for Rheumatoid Arthritis. To read article click here.

-03/07/2006-

Press Release: Available from Velocity11, a pioneer in automation technology solutions for life science laboratories, BenchCel™ is a robust benchtop microplate handling system that delivers the speed and precision of much larger and more expensive automation platforms. To read press release click here.

Press Release: Integra Biosciences has announced a series of new products, options and applications solutions will premiere at the forthcoming Analytica exhibition in Munich, Germany (25th-28th April 2006). To read press release click here.

Compugen Ltd. leads consortium to model MAP-kinase pathway. To read article click here.

-03/06/2006-

Invitrogen Corp. and NIH Chemical Genomics Center form chemical genetics research collaboration. To read article click here.

-03/03/2006-

Press Release: FMC acquires global all product ChemAxon licenses and switches over to JChem structure search platform. To read press release click here.

Recombinomics Inc. identifies American sequences in the H5N1 (Avian Flu) virus. To read article click here.

-03/02/2006-

FDA approves Rituxan for moderate-to-severe rheumatoid arthritis treatment. To read article click here.

-03/01/2006-

Press Release: Warwick Analytical Service, the analytical division of Exeter Analytical (UK) Ltd., is able to investigate and precisely measure the optical activity of samples with an accuracy of +/- 0.002 degrees for optical rotations of less than 1 degree. To read press release click here.

FDA approves Erbitux® (Cetuximab) for treatment of head and neck cancer. To read article click here.

Pfizer completes the acquisition of Exubera from Sanofi-Aventis. To read article click here.